SEC Comment Letter 0000000000-22-012378 to TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc.
Date: Nov. 15, 2022 · CIK: 0001783328 · Accession: 0000000000-22-012378
AI Filing Summary & Sentiment
File numbers found in text: 333-268260
Letter
United States securities and exchange commission logo November 15, 2022 David Southwell President and Chief Executive Officer TScan Therapeutics, Inc. 830 Winter Street Waltham, Massachusetts 02451 Re:TScan Therapeutics, Inc. Registration Statement on Form S-3 Filed November 9, 2022 File No. 333-268260 Dear David Southwell: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: William D. Collins, Esq.
Show Raw Text
United States securities and exchange commission logo
November 15, 2022
David Southwell
President and Chief Executive Officer
TScan Therapeutics, Inc.
830 Winter Street
Waltham, Massachusetts 02451
Re:TScan Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 9, 2022
File No. 333-268260
Dear David Southwell:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: William D. Collins, Esq.